Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

Mei HE, Schmidt S, Dörner T.

Arthritis Res Ther. 2012;14 Suppl 5:S1. doi: 10.1186/ar3909. Epub 2012 Nov 8. Review.

2.

CD19: a promising B cell target for rheumatoid arthritis.

Tedder TF.

Nat Rev Rheumatol. 2009 Oct;5(10):572-7. doi: 10.1038/nrrheum.2009.184. Review.

PMID:
19798033
3.

Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.

Chen D, Ireland SJ, Davis LS, Kong X, Stowe AM, Wang Y, White WI, Herbst R, Monson NL.

J Immunol. 2016 Feb 15;196(4):1541-9. doi: 10.4049/jimmunol.1501376. Epub 2016 Jan 13.

4.

Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

Yazawa N, Hamaguchi Y, Poe JC, Tedder TF.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15178-83. Epub 2005 Oct 10.

5.

B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.

Harvey PR, Gordon C.

BioDrugs. 2013 Apr;27(2):85-95. doi: 10.1007/s40259-013-0015-8.

PMID:
23456653
6.

Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice.

Gallagher S, Turman S, Yusuf I, Akhgar A, Wu Y, Roskos LK, Herbst R, Wang Y.

Int Immunopharmacol. 2016 Jul;36:205-212. doi: 10.1016/j.intimp.2016.04.035. Epub 2016 May 7.

PMID:
27163209
7.

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.

Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang CH.

Blood. 2013 Oct 24;122(17):3020-9. doi: 10.1182/blood-2012-12-473744. Epub 2013 Jul 2.

8.

Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.

Rossi EA, Chang CH, Goldenberg DM.

PLoS One. 2014 May 19;9(5):e98315. doi: 10.1371/journal.pone.0098315. eCollection 2014.

9.

A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE.

Nicholas MW, Dooley MA, Hogan SL, Anolik J, Looney J, Sanz I, Clarke SH.

Clin Immunol. 2008 Feb;126(2):189-201.

10.

Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.

Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A.

Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.

PMID:
20678160
11.

B-cell-targeted therapy for systemic lupus erythematosus.

Sabahi R, Anolik JH.

Drugs. 2006;66(15):1933-48.

PMID:
17100405
12.

Long-lived plasma cells and their contribution to autoimmunity.

Hoyer BF, Manz RA, Radbruch A, Hiepe F.

Ann N Y Acad Sci. 2005 Jun;1050:124-33. Review.

PMID:
16014527
13.

[B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].

Tanaka Y.

Yakugaku Zasshi. 2009 Jun;129(6):675-9. Review. Japanese.

14.

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.

Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I.

Arthritis Rheum. 2004 Nov;50(11):3580-90.

15.

Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.

Dörner T.

J Rheumatol Suppl. 2006 May;77:3-11. Review.

PMID:
16652439
16.

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.

Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM.

Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485. Review.

17.

Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss.

Culton DA, Nicholas MW, Bunch DO, Zhen QL, Kepler TB, Dooley MA, Mohan C, Nachman PH, Clarke SH.

J Clin Immunol. 2007 Jan;27(1):53-68. Epub 2006 Dec 29.

PMID:
17195045
18.

[B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].

Kondo S, Akashi T, Katsuta H, Iwakiri R, Anzai K, Nagafuchi S, Niho Y, Harada M.

Fukuoka Igaku Zasshi. 2005 Apr;96(4):86-92. Review. Japanese.

PMID:
15991605
19.

B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.

Looney RJ.

Rheumatology (Oxford). 2005 May;44 Suppl 2:ii13-ii17. Review.

PMID:
15851522
20.

CD19 as an attractive target for antibody-based therapy.

Hammer O.

MAbs. 2012 Sep-Oct;4(5):571-7. doi: 10.4161/mabs.21338. Epub 2012 Jul 23. Review.

Supplemental Content

Support Center